386 related articles for article (PubMed ID: 29788332)
1. Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy.
Kurokawa C; Iankov ID; Anderson SK; Aderca I; Leontovich AA; Maurer MJ; Oberg AL; Schroeder MA; Giannini C; Greiner SM; Becker MA; Thompson EA; Haluska P; Jentoft ME; Parney IF; Weroha SJ; Jen J; Sarkaria JN; Galanis E
J Natl Cancer Inst; 2018 Oct; 110(10):1123-1132. PubMed ID: 29788332
[TBL] [Abstract][Full Text] [Related]
2. Modulation of the Type I Interferon Response Defines the Sensitivity of Human Melanoma Cells to Oncolytic Measles Virus.
Allagui F; Achard C; Panterne C; Combredet C; Labarrière N; Dréno B; Elgaaied AB; Pouliquen D; Tangy F; Fonteneau JF; Grégoire M; Boisgerault N
Curr Gene Ther; 2017; 16(6):419-428. PubMed ID: 28042780
[TBL] [Abstract][Full Text] [Related]
3. Engineering oncolytic measles virus to circumvent the intracellular innate immune response.
Haralambieva I; Iankov I; Hasegawa K; Harvey M; Russell SJ; Peng KW
Mol Ther; 2007 Mar; 15(3):588-97. PubMed ID: 17245355
[TBL] [Abstract][Full Text] [Related]
4. Transcriptome Analysis of Human Glioblastoma Cells Susceptible to Infection with the Leningrad-16 Vaccine Strain of Measles Virus.
Ammour Y; Susova O; Krasnov G; Nikolaeva E; Varachev V; Schetinina Y; Gavrilova M; Mitrofanov A; Poletaeva A; Bekyashev A; Faizuloev E; Zverev VV; Svitich OA; Nasedkina TV
Viruses; 2022 Nov; 14(11):. PubMed ID: 36366531
[TBL] [Abstract][Full Text] [Related]
5. Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors.
Speck T; Heidbuechel JPW; Veinalde R; Jaeger D; von Kalle C; Ball CR; Ungerechts G; Engeland CE
Clin Cancer Res; 2018 May; 24(9):2128-2137. PubMed ID: 29437789
[No Abstract] [Full Text] [Related]
6. Carcinoembryonic antigen-expressing oncolytic measles virus derivative in recurrent glioblastoma: a phase 1 trial.
Galanis E; Dooley KE; Keith Anderson S; Kurokawa CB; Carrero XW; Uhm JH; Federspiel MJ; Leontovich AA; Aderca I; Viker KB; Hammack JE; Marks RS; Robinson SI; Johnson DR; Kaufmann TJ; Buckner JC; Lachance DH; Burns TC; Giannini C; Raghunathan A; Iankov ID; Parney IF
Nat Commun; 2024 Jan; 15(1):493. PubMed ID: 38216554
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic measles virus strains have significant antitumor activity against glioma stem cells.
Allen C; Opyrchal M; Aderca I; Schroeder MA; Sarkaria JN; Domingo E; Federspiel MJ; Galanis E
Gene Ther; 2013 Apr; 20(4):444-9. PubMed ID: 22914495
[TBL] [Abstract][Full Text] [Related]
8. Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy.
Reddi HV; Madde P; McDonough SJ; Trujillo MA; Morris JC; Myers RM; Peng KW; Russell SJ; McIver B; Eberhardt NL
Cancer Gene Ther; 2012 Sep; 19(9):659-65. PubMed ID: 22790962
[TBL] [Abstract][Full Text] [Related]
9. Heat shock protein inhibitors increase the efficacy of measles virotherapy.
Liu C; Erlichman C; McDonald CJ; Ingle JN; Zollman P; Iankov I; Russell SJ; Galanis E
Gene Ther; 2008 Jul; 15(14):1024-34. PubMed ID: 18356818
[TBL] [Abstract][Full Text] [Related]
10. Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models.
Saha D; Wakimoto H; Peters CW; Antoszczyk SJ; Rabkin SD; Martuza RL
Clin Cancer Res; 2018 Jul; 24(14):3409-3422. PubMed ID: 29599413
[No Abstract] [Full Text] [Related]
11. JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models.
Patel MR; Dash A; Jacobson BA; Ji Y; Baumann D; Ismail K; Kratzke RA
Cancer Gene Ther; 2019 Nov; 26(11-12):411-418. PubMed ID: 30622322
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropism.
Leber MF; Bossow S; Leonard VH; Zaoui K; Grossardt C; Frenzke M; Miest T; Sawall S; Cattaneo R; von Kalle C; Ungerechts G
Mol Ther; 2011 Jun; 19(6):1097-106. PubMed ID: 21468006
[TBL] [Abstract][Full Text] [Related]
13. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter.
Hasegawa K; Pham L; O'Connor MK; Federspiel MJ; Russell SJ; Peng KW
Clin Cancer Res; 2006 Mar; 12(6):1868-75. PubMed ID: 16551872
[TBL] [Abstract][Full Text] [Related]
14. Engineered measles virus as a novel oncolytic therapy against prostate cancer.
Msaouel P; Iankov ID; Allen C; Morris JC; von Messling V; Cattaneo R; Koutsilieris M; Russell SJ; Galanis E
Prostate; 2009 Jan; 69(1):82-91. PubMed ID: 18973133
[TBL] [Abstract][Full Text] [Related]
15. Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma.
Nakashima H; Nguyen T; Kasai K; Passaro C; Ito H; Goins WF; Shaikh I; Erdelyi R; Nishihara R; Nakano I; Reardon DA; Anderson AC; Kuchroo V; Chiocca EA
Clin Cancer Res; 2018 Jun; 24(11):2574-2584. PubMed ID: 29511029
[No Abstract] [Full Text] [Related]
16. MicroRNA-mediated multi-tissue detargeting of oncolytic measles virus.
Baertsch MA; Leber MF; Bossow S; Singh M; Engeland CE; Albert J; Grossardt C; Jäger D; von Kalle C; Ungerechts G
Cancer Gene Ther; 2014 Sep; 21(9):373-80. PubMed ID: 25145311
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma.
Dispenzieri A; Tong C; LaPlant B; Lacy MQ; Laumann K; Dingli D; Zhou Y; Federspiel MJ; Gertz MA; Hayman S; Buadi F; O'Connor M; Lowe VJ; Peng KW; Russell SJ
Leukemia; 2017 Dec; 31(12):2791-2798. PubMed ID: 28439108
[TBL] [Abstract][Full Text] [Related]
18. Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy.
Panagioti E; Kurokawa C; Viker K; Ammayappan A; Anderson SK; Sotiriou S; Chatzopoulos K; Ayasoufi K; Johnson AJ; Iankov ID; Galanis E
J Clin Invest; 2021 Jul; 131(13):. PubMed ID: 34196308
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic measles virus retargeting by ligand display.
Msaouel P; Iankov ID; Allen C; Russell SJ; Galanis E
Methods Mol Biol; 2012; 797():141-62. PubMed ID: 21948475
[TBL] [Abstract][Full Text] [Related]
20. Potential and clinical translation of oncolytic measles viruses.
Robinson S; Galanis E
Expert Opin Biol Ther; 2017 Mar; 17(3):353-363. PubMed ID: 28129716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]